Antoinette Tan is an Oncology physician affiliated with Levine Cancer Institute. OpenAlex indexes 235 publications with 9,887 citations (h-index 43); ClinicalTrials.gov lists 9 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1021 Morehead Medical Dr
Ste A
Charlotte, NC 282042990
Telephone
980-442-2000Registry record last updated 15 Jul 2024.
Clinical trials
- Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer
Sponsor: Wake Forest University Health Sciences
- LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer
Sponsor: Wake Forest University Health Sciences
- Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer
Sponsor: Wake Forest University Health Sciences
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
15 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- JAZZ PHARMACEUTICALS INC.Program year20252 payments
- Genentech USA, Inc.Program year20253 payments
- Daiichi Sankyo Inc.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Aromatase Inhibitor100%Anastrozole60%Letrozole40%Part D≥29 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Checkpoint inhibitor therapy for metastatic triple-negative breast cancer
Cancer and Metastasis Reviews
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Peter Voorhees, MD
Levine Cancer Institute
Edward Copelan, MD
Levine Cancer Institute
Nilanjan Ghosh, MD
Levine Cancer Institute
Stuart Burri, MD
Levine Cancer Institute
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”